Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23605968 | 0.87 | KMT2A (0.38) | ALDH1A1MEN1KMT2AGAAPPARG | |
| SCHEMBL21991869 | 0.87 | MTNR1A (0.48) | LDHAKDM4EALDH1A1SMN1; SMN2PPARG | |
| SCHEMBL21991880 | 0.86 | ALDH1A1 (0.39) | LDHAKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL21991861 | 0.86 | PPARG (0.41) | ALDH1A1MEN1KMT2AGAAPPARG | |
| SCHEMBL21991532 | 0.86 | NPSR1 (0.42) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21991611 | 0.86 | PPARG (0.41) | ALDH1A1MEN1KMT2AGAAPPARG | |
| SCHEMBL21991602 | 0.86 | PPARG (0.41) | ALDH1A1MEN1KMT2AGAAPPARG | |
| SCHEMBL21992661 | 0.85 | KMT2A (0.44) | LDHAKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL21992649 | 0.83 | MEN1 (0.38) | LDHAKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL21991266 | 0.83 | PPARG (0.43) | ALDH1A1PPARGPPARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | LDHA 3139/4885KDM4E 4518/4885ALDH1A1 932/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | LDHA 3139/4885KDM4E 4518/4885ALDH1A1 932/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | LDHA 3139/4885KDM4E 4518/4885ALDH1A1 932/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | LDHA 3139/4885KDM4E 4518/4885ALDH1A1 932/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | LDHA 3139/4885KDM4E 4518/4885ALDH1A1 932/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | LDHA 3139/4885KDM4E 4518/4885ALDH1A1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.